Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTNNk42KM7:TR?= M1vrSFEuPCCm NGfaNZFFVVOR MnL6[Y5p[W6lZYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiC2cnXheI1mdnRid3n0bEB1[W2xeHnm[Y4> MXGyOVQ6ODN6Mx?=
H1703 MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUSyMlUh|ryP MWixMVQh\A>? NYjBTZhFTE2VTx?= MWnlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> NEXMfIIzPTR7MEO4Ny=>
HUVECs M{CycmN6fG:2b4jpZ4l1gSCDc4PhfS=> M4Ti[VExOCCwTR?= NVPY[ot[OjRiaB?= MoqyZZR1\W63YYTld{B1cGViYXLyc4difGm4ZTDl[oZm[3S|IH;mJINidHmlb4PpckBwdiCYUlmtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NV3GeGViOjV2NUCxPFY>
APRE-19 M{\vTWFxd3C2b4Ppd{BCe3OjeR?= M1fLS|Uh|ryP MXWyOEBp NX;IPVk5[WKxbHnzbIV{KE[OWj3t[YRq[XSnZDDwdo8ue3W{dnn2ZYww[W62aT3hdI9xfG:|aYOgZYN1cX[rdIm= NWfaU|JHOjV|Mkm2NVc>
MDA-MB-231 NHO2WFhCeG:ydH;zbZMhSXO|YYm= NYLvZXRnOcLizszNxsA> NGjFZ2g1QCCq M1;x[GROW09? MVnk[YNz\WG|ZYOgeIhmKGOnbHygd5Vzfmm4YXygeJJm[XSnZDD3bZRpKDJ3IN88UUBw\iCIMTDvdkBHOiEEoB?= M1[wWVI2OzByOUOy
MCF7 MmHDSpVv[3Srb36gRZN{[Xl? M2D2XlExOCCwTR?= MmPLNlQhcA>? NHfR[3dmdGmvaX7heIV{KEV{LXnu[JVk\WRiQWLFMWx2[yCjY4Tpeol1gQ>? NWjDPVJJOjVzN{K1OVc>
HT-29  NGDmbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{j3dlEvPcLiwsXN MlW5PVYhcA>? NWnlNm86\GWlcnXhd4V{KGOnbHyg[5Jwf3SqIIfobYNpKGOjbjDi[UBqdmirYnn0[YQh[nliS2nORS=> NF\FfIgzPTBzMkGyNy=>
MO59K  NIniPWdEgXSxdH;4bYNqfHliQYPzZZk> NH\VSVU2yqEQvF2= MoXqO{Bl NIjhVJZFVVOR NX3mZoVZ\W6qYX7j[ZMhfGinIHP5eI91d3irY3n0fUBw\iCndH;wc5Nq\GVib4KgZ4l{eGyjdHnu NVfWW3FOOjR7NUO1OlE>
MO59J MkewR5l1d3SxeHnjbZR6KEG|c3H5 NWHVZotyPcLizszN MnKwO{Bl NXr5Ro8xTE2VTx?= MmfV[Y5p[W6lZYOgeIhmKGO7dH;0c5hq[2m2eTDv[kBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw NEK0c4kzPDl3M{W2NS=>
MO59K  NULBe2p6SXCxcITvd4l{KEG|c3H5 MkDlNVAh|ryP MnjyNlQhcA>? M1rz[2ROW09? NVfZcndlcW6lcnXhd4V{KHSqZTDEV2IhdGW4ZXygbY5lfWOnZDDifUBmfG:yb4Pp[IUhd3JiY3nzdIxifGmw MXWyOFk2OzV4MR?=
MO59J NFHYNm5CeG:ydH;zbZMhSXO|YYm= M1P1S|ExKM7:TR?= NYDXbXdmOjRiaB?= MWrEUXNQ NGnjNHhqdmO{ZXHz[ZMhfGinIFTTRkBt\X[nbDDpcoR2[2WmIHL5JIV1d3Cxc3nk[UBweiClaYPwcIF1cW5? NEKxbnEzPDl3M{W2NS=>
HepG2 Mk\BSpVv[3Srb36gRZN{[Xl? MW[xNFAhdk1? M{XXVlAvPSCq NYrYOnlKTE2VTx?= NXrGXoRk[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? NF;wSY4zPDh4M{O1NC=>
A549  NHrURpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml\iN{DDvU4EoB?= MmTUNkBp MmXXd5VxeHKnc4Pld{Bx\W2ndILlfIVlNWmwZIXj[YQhSWu2IHHu[EBIW0t|zsKgZYN1cX[jdHnvckwhWy2yaHHz[UBienKnc4SsJINmdGxiYYDvdJRwe2m|IHHu[EBk[XOyYYPlMVMh[WO2aY\heIlwdg>? MYKyOFg1Pzh4Mx?=
A549  M{TvUWZ2dmO2aX;uJGF{e2G7 MkfTNVDDqM7:bdMg NXHYdIxKOTZiaB?= NUj3SIxvTE2VTx?= MYHtc4R2dGG2ZYOgeIhmKEmDVjDy[ZBtcWOjdHnvckBidmRiY3H1d4V{KHKndHXueIlwdiCxZjDOVEBqdiC2aHWgcpVkdGW3cz6= M1X1RVI1QDB{MUGx
SK-N-LO MV3GeY5kfGmxbjDBd5NigQ>? NVfhVIdtOTByIH7N Mmn1NE42KGh? Ml2w[IVkemWjc3XzJJRp\SC|dHnteYxidnRiZX\m[YN1eyCxZjDtc5JxcGmwZTDvckBCc3RicHjvd5Bpd3K7bHH0bY9v Ml;TNlQ3PTR4ME[=
HL-60 NWDPPYFjTnWwY4Tpc44hSXO|YYm= NHzWN3kxNjIEoN88US=> MVi3NkBp NIG5VZFjdG:la4Og[IF{[XSrbnniMYlv\HWlZXSgZ4VtdCCmaX\m[ZJmdnSrYYTpc44> NUHONoh6OjR4MEeyO|M>
HepG2  M3HRVmZ2dmO2aX;uJGF{e2G7 MmW1NlAxKG6P NGfsbXIxNjViaB?= MoPTZZR1\W63YYTld{BHd3iRIIDoc5NxcG:{eXzheIlwdg>? NHHBcWQzPDV|NUG5Ni=>
H520 M3XwbmZ2dmO2aX;uJGF{e2G7 MoixNVDDqM7:TR?= MYWxJIg> MVTEUXNQ NX:yUFNb\GWlcnXhd4V{KGOnbHz1cIFzKHCqb4PwbI8uSUuWIIDyc5RmcW5ibHX2[Yx{ NIL2NXczPDR2N{mzOS=>
H1975 MXPGeY5kfGmxbjDBd5NigQ>? MYGxNOKh|ryP MUKxJIg> NX73emtITE2VTx?= Mkjr[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz NGfBeoYzPDR2N{mzOS=>
MG-63 NH:2R2RCeG:ydH;zbZMhSXO|YYm= NUjEcHgzOTBiwsXN NEfy[WoyOiCq M1vaPIVvcGGwY3XzJGRRNWmwZIXj[YQh[XCxcITvd4l{ NV:3[nNuOjR|NUizNFE>
5637 MkPwRZBweHSxc3nzJGF{e2G7 M1PpWFExyqEQvF2= M{jie|QxKG2rbh?= MU\y[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> M3\PSVI1OzN|OE[4
HEK-293 NWLZbGxETnWwY4Tpc44hSXO|YYm= MWKxOVBvVQ>? NV3UZZh{OTZiaB?= MWHEUXNQ MVjk[YNz\WG|ZYOgR3JVKGGldHn2bZR6 MmjONlQ{OjR|Nk[=
SW480  MmHVSpVv[3Srb36gRZN{[Xl? Mm\aNVUxdk1? MnjONlAhcA>? MUHEUXNQ NH3XbVZz\WS3Y3XzJINmdGy3bHHyJIFk[3WvdXzheIlwdiCxZjFOtk1k[XSnbnnu M2LJd|I1OzJ2M{[2
HepG2 NGjyc2RHfW6ldHnvckBCe3OjeR?= M2S3Z|ExOCCwTR?= M1\vWVI1KGh? MlLKZZR1\W63YYTld{B1cGViY3;sc45q\XNib3[geIhmKHS3bX;yJINmdGy|IIfpeIghfXC{ZXf1cIF1cW:wIH;mJGFsfDF? NIH3e4szPDJ7N{WxNC=>
HCT 116  NVTEfppkTnWwY4Tpc44hSXO|YYm= NHn1fGgyODBibl2= NX7ZdlR6OjRiaB?= M1;HTIF1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz NFHGNm0zPDJ7N{WxNC=>
BEL/FU NHP3XIxHfW6ldHnvckBCe3OjeR?= M172[FEhdU1? M4XU[FI1KGh? MljM[IVkemWjc3XzJJBzd3SnaX6gcIV3\Wy|IH;mJJRp\SCSSUPLM2FsfCCyYYToe4F6 M1y5WFI1OjN{MEm5
Huh7  MXnGeY5kfGmxbjDBd5NigQ>? NVPrSGc2O8LizszN MoXWNUBp NG[0ZYtz\WS3Y3XzJJRp\SC4aYL1d{BmdnS{eTDpcpRwKHSqZTDj[Yxtew>? Mm[zNlQyQDRzOU[=
A-375 NYCwS286SXCxcITvd4l{KEG|c3H5 M1:3dVQwQCEQvF2= MX:yOEBp NYDhVmlN\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> NHjuN5QzPDFzM{G3Ny=>
A-375-TS  MmXyRZBweHSxc3nzJGF{e2G7 MXu0M|gh|ryP MXqyOEBp M{LEWoVvcGGwY3XzJHRTSUmOLXnu[JVk\WRiYYDvdJRwe2m|wrC= NEf6eoYzPDFzM{G3Ny=>
Mel-HO MW\BdI9xfG:|aYOgRZN{[Xl? MlXMOE85KM7:TR?= MWGyOEBp MmfJ[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= NYLNfpFCOjRzMUOxO|M>
Mel-HO-TS NFHw[nJCeG:ydH;zbZMhSXO|YYm= NUDSbGxMPC96IN88US=> M3zE[lI1KGh? NG\zVJBmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MlTQNlQyOTNzN{O=
MeWo Mor6RZBweHSxc3nzJGF{e2G7 NYjQe41lPC96IN88US=> NGrhUIgzPCCq NFXROY5mdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg NV;sS2U3OjRzMUOxO|M>
Mel-2a MWPBdI9xfG:|aYOgRZN{[Xl? NE\mdGc1NzhizszN MXWyOEBp NIXrZ5pmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MnnwNlQyOTNzN{O=
MDA-MB-231 NInwPJhHfW6ldHnvckBCe3OjeR?= MmPHNQKBmzRyMDDuUS=> MUO0JIg> MWfzeZBxemW|c3XzJGFsfCCyaH;zdIhwenmuYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NI\6e2gzOjlyNkK1PS=>
MDA-MB-231 NVjUcmVbTnWwY4Tpc44hSXO|YYm= NHHZfFI1ODBibl2= NX\INJB5PCCq NELXVIll\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXiyNlkxPjJ3OR?=
Jurkat NEjNZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDCNE4zPS1zLkK1JO69VQ>? NXzwRZJmOjRxNEigbC=> M3PkU2ROW09? NVrlc|IxcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= MYqxPVc2PzF6NR?=
Namalwa M33WT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjSNo1WOC5{NT2xMlI2KM7:TR?= NXXJU|B[OjRxNEigbC=> MYLEUXNQ NYXFdItPcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3WtJIRmeGWwZHXueEBu[W6wZYK= NYjXcGc3OTl5NUexPFU>
Jurkat MnjQRZBweHSxc3nzJGF{e2G7 MXiwMlI2NTFwMkWg{txO NEnrd5MzPC92ODDo MkPOSG1UVw>? M{\tfolv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCC2aX3lMUBidmRiZH;z[U0h\GWyZX7k[Y51KG2jbn7ldi=> M1v0VVE6PzV5MUi1
Namalwa MYfBdI9xfG:|aYOgRZN{[Xl? M{DKbFAvOjVvMT6yOUDPxE1? MVWyOE81QCCq MYrEUXNQ MkXHbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy MYOxPVc2PzF6NR?=
K562 MlLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVyyOEBp M{jFZmlEPTB;MkZCtVAvOTRibl2= NYiyTlhYOTl4NkKzOlE>
SW1990 M4HTTGZ2dmO2aX;uJGF{e2G7 M2q3bFAvODFvMTFOwG0> NIjQVXkyKGh? M4Xa[YlvcGmkaYTzJGhCNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? M{fvd|E6PDZ7MEKw
RT112  NIjpbmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHLNJUyOMLizszN NHPHSGQzPCCq MnGzSG1UVw>? NV\USJE5\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKEd{L12gZ4VtdHN? MknrNVg4QDd6M{K=
MHG-U1 M3XHOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmizNVDDqM7:TR?= M{j3NFI1KGh? M4DWNmROW09? NGO4UHdl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4YhTzJxTTDj[Yxtew>? NVr3d3l5OTh5OEe4N|I>
SMMC-7721 MoXDRZBweHSxc3nzJGF{e2G7 MWiyNFDDqG6P MmjzNlQhcA>? M{PNfolv[3KnYYPld{BEUFhvaX7keYNm\CCjcH;weI9{cXN? MV:xO|U2PzF7MR?=
SMMC-7721 NYjVdolpTnWwY4Tpc44hSXO|YYm= M1G2ZVIxOMLibl2= MYGyOEBp MUj1dE1z\We3bHH0[ZMh|rJzLETHWFEh\XiycnXzd4lwdg>? NX7UVYhQOTd3NUexPVE>
HeLa MoX4SpVv[3Srb36gRZN{[Xl? MYWxNFDDqG6PwrC= NEjuT3IyKGh? MnzlZYx1\XK|IITo[UBud3KyaH;sc4d6KG:oIITo[UB1emGwc3\ldpJqdiC{ZXP5Z4xqdmdiY3;tdIFzfG2nboS= NGXjeZMyPjh7MEmxOS=>
MRC5VI M1HaR2Z2dmO2aX;uJGF{e2G7 M2XXNlEzNjVibV2= MVuwMlUhcA>? MV;EUXNQ MUjhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> Mm\xNVYzOjd|OUS=
AT5BIVA MnXzSpVv[3Srb36gRZN{[Xl? MUOxNk42KG2P MX2wMlUhcA>? NFHDUYRFVVOR M3;ObYFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh M4fEPVE3OjJ5M{m0
M059J NGrpc4RHfW6ldHnvckBCe3OjeR?= NETGWFMyOi53IH3N NYjqTmlQOC53IHi= MknTSG1UVw>? MVjhZo9tcXOqZYOgeIhmKFOnckS3N{9VcHJ|MElCpJBpd3OyaH;yfYxifGmxbjDv[kBCc3SSS1NCpC=> M4LPelE3OjJ5M{m0
HeLa M2LkUGZ2dmO2aX;uJGF{e2G7 NXflZWJXOTJwNTDtUS=> M{POXlAvPSCq M2q1ZmROW09? NEXqcFNi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? M2\MVlE3OjJ5M{m0
N2a M3fj[WFxd3C2b4Ppd{BCe3OjeR?= MnvnNE4yNTFyIN88US=> NIS5eJUzKGh? MV;pcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NYfnWFl6OTV6NEK3Olc>
Jurkat  NILPV3JMcW6jc3WgRZN{[Xl? M1\2TWlEPTBib3[gNlQhdk1? NYPEWIZqOTV4NkS1NVk>

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
5%DMSO+corn oil
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID